(Q48581092)

13 February 2018

editorial

0 references

title

Another view of therapy for cognition in schizophrenia. (English)

1 reference

13 February 2018

0 references

William T Carpenter

1

1 reference

13 February 2018

James M Gold

series ordinal

2

1 reference

13 February 2018

language of work or name

English

0 references

publication date

1 June 2002

1 reference

13 February 2018

published in

Biological Psychiatry

1 reference

13 February 2018

volume

51

1 reference

13 February 2018

page(s)

969-971

1 reference

13 February 2018

issue

12

1 reference

13 February 2018

Uneasy alliance--clinical investigators and the pharmaceutical industry

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901399-9

The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901399-9

Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901399-9

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901399-9

What are the functional consequences of neurocognitive deficits in schizophrenia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901399-9

The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901399-9

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901399-9

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901399-9

One hundred years of schizophrenia: a meta-analysis of the outcome literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901399-9

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901399-9

Risperidone versus haloperidol on secondary memory: can newer medications aid learning?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901399-9

The effect of neuroleptics on cognitive and psychomotor function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901399-9

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901399-9

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901399-9

Does cognitive function improve with quetiapine in comparison to haloperidol?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901399-9

Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901399-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(02)01399-9

1 reference

13 February 2018

PubMed ID

12062880

1 reference

13 February 2018